Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGN Align Technology	$190.77 -0.8%	$186.00	$141.74 ▼ $262.87	$13.83B	1.63	922,320 shs	474,609 shs
ARGX argenex	$564.59 -1.4%	$563.91	$457.42 ▼ $678.21	$34.55B	0.37	331,501 shs	336,884 shs
BSX Boston Scientific	$103.68 -0.9%	$103.42	$71.88 ▼ $107.53	$153.33B	0.68	6.75 million shs	8.57 million shs
ILMN Illumina	$96.14 -1.8%	$89.22	$68.70 ▼ $156.66	$15.22B	1.36	2.16 million shs	1.89 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGN Align Technology	0.00%	-5.69%	+5.98%	+11.29%	-23.87%
ARGX argenex	0.00%	+0.78%	+4.96%	-5.30%	+21.83%
BSX Boston Scientific	0.00%	+0.50%	+2.29%	+9.05%	+33.92%
ILMN Illumina	0.00%	-3.13%	+6.51%	+35.01%	-19.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGN Align Technology	4.8677 of 5 stars	4.3	5.0	3.8	3.2	1.7	1.3
ARGX argenex	4.4042 of 5 stars	4.5	3.0	0.0	3.4	1.7	2.5
BSX Boston Scientific	4.6917 of 5 stars	3.6	3.0	4.2	3.9	2.5	1.3
ILMN Illumina	4.8883 of 5 stars	4.2	3.0	4.2	3.9	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGN Align Technology	2.67	Moderate Buy	$242.92	27.33% Upside
ARGX argenex	3.10	Buy	$728.06	28.95% Upside
BSX Boston Scientific	3.13	Buy	$116.09	11.97% Upside
ILMN Illumina	2.40	Hold	$125.11	30.13% Upside

Current Analyst Ratings Breakdown

Latest ALGN, BSX, ARGX, and ILMN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	ILMN Illumina	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Sector Outperform ➝ Sector Perform	$125.00
7/9/2025	ALGN Align Technology	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$200.00 ➝ $220.00
7/9/2025	ILMN Illumina	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell	$85.00 ➝ $80.00
7/8/2025	ARGX argenex	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy
7/8/2025	ILMN Illumina	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$116.00 ➝ $128.00
7/3/2025	ARGX argenex	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$700.00
7/1/2025	ARGX argenex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$720.00
6/24/2025	ARGX argenex	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$715.00
6/24/2025	ILMN Illumina	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Underweight ➝ Underweight	$77.00 ➝ $85.00
6/16/2025	BSX Boston Scientific	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/16/2025	BSX Boston Scientific	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$118.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGN Align Technology	$3.98B	3.47	$8.99 per share	21.22	$51.60 per share	3.70
ARGX argenex	$2.25B	15.34	$2.97 per share	190.07	$90.49 per share	6.24
BSX Boston Scientific	$16.75B	9.16	$3.65 per share	28.39	$14.93 per share	6.94
ILMN Illumina	$4.37B	3.48	$4.69 per share	20.49	$14.96 per share	6.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGN Align Technology	$421.36M	$5.49	34.75	21.32	2.02	10.29%	13.52%	8.36%	7/30/2025 (Confirmed)
ARGX argenex	$833.04M	$16.21	34.83	52.04	0.98	40.20%	16.15%	14.33%	7/31/2025 (Estimated)
BSX Boston Scientific	$1.85B	$1.37	75.68	32.10	2.69	11.58%	18.67%	10.38%	7/23/2025 (Estimated)
ILMN Illumina	-$1.22B	-$6.07	N/A	18.63	1.88	-22.25%	25.54%	8.62%	7/31/2025 (Estimated)

Latest ALGN, BSX, ARGX, and ILMN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/31/2025	Q2 2025	ARGX argenex	$2.87	N/A	N/A	N/A	$776.82 million	N/A
7/31/2025	Q2 2025	ILMN Illumina	$1.02	N/A	N/A	N/A	$1.12 billion	N/A
7/30/2025	Q2 2025	ALGN Align Technology	$2.57	N/A	N/A	N/A	$1.06 billion	N/A
7/23/2025	Q2 2025	BSX Boston Scientific	$0.72	N/A	N/A	N/A	$4.89 billion	N/A
5/8/2025	Q1 2025	ARGX argenex	$2.32	$2.58	+$0.26	$2.58	$748.34 million	$1.35 billion
5/8/2025	Q1 2025	ILMN Illumina	$0.96	$0.97	+$0.01	$0.82	$1.03 billion	$1.04 billion
4/30/2025	Q1 2025	ALGN Align Technology	$2.00	$2.13	+$0.13	$1.27	$977.90 million	$979.26 million
4/23/2025	Q1 2025	BSX Boston Scientific	$0.67	$0.75	+$0.08	$0.45	$4.57 billion	$4.66 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGN Align Technology	N/A	N/A	N/A	N/A	N/A
ARGX argenex	N/A	N/A	N/A	N/A	N/A
BSX Boston Scientific	N/A	N/A	N/A	N/A	N/A
ILMN Illumina	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGN Align Technology	N/A	1.21	1.08
ARGX argenex	N/A	7.29	6.68
BSX Boston Scientific	0.47	1.45	0.88
ILMN Illumina	0.63	1.86	1.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGN Align Technology	88.43%
ARGX argenex	60.32%
BSX Boston Scientific	89.07%
ILMN Illumina	89.42%

Insider Ownership

Company	Insider Ownership
ALGN Align Technology	0.66%
ARGX argenex	2.43%
BSX Boston Scientific	0.50%
ILMN Illumina	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGN Align Technology	20,945	72.49 million	72.01 million	Optionable
ARGX argenex	1,599	61.20 million	59.71 million	Optionable
BSX Boston Scientific	53,000	1.48 billion	1.47 billion	Optionable
ILMN Illumina	9,030	158.30 million	154.18 million	Optionable

ALGN, BSX, ARGX, and ILMN Headlines

Recent News About These Companies

Carmel Capital Partners LLC Sells 10,931 Shares of Illumina, Inc. (NASDAQ:ILMN)

4 hours ago | marketbeat.com

Massachusetts Financial Services Co. MA Sells 705,627 Shares of Illumina, Inc. (NASDAQ:ILMN)

July 20 at 4:40 AM | marketbeat.com

Q2 Earnings Estimate for Illumina Issued By Leerink Partnrs

July 20 at 2:29 AM | americanbankingnews.com

Illumina, Inc. (NASDAQ:ILMN) Shares Purchased by New York State Common Retirement Fund

July 19 at 4:22 AM | marketbeat.com

Q2 Earnings Forecast for Illumina Issued By Leerink Partnrs

July 18 at 9:34 AM | marketbeat.com

Cwm LLC Buys 17,967 Shares of Illumina, Inc. (NASDAQ:ILMN)

July 18 at 4:45 AM | marketbeat.com

Illumina Stock: What Went Wrong And Why It's Best To Stay Away

July 17 at 8:36 AM | benzinga.com

Illumina Stock: What Went Wrong And Why It's Best To Stay Away

July 17 at 7:45 AM | benzinga.com

Illumina India wins the 2025 GCC Workplace Awards

July 17 at 6:57 AM | pharmabiz.comP

Kornitzer Capital Management Inc. KS Cuts Stock Position in Illumina, Inc. (NASDAQ:ILMN)

July 17 at 6:30 AM | marketbeat.com

Nisa Investment Advisors LLC Sells 19,162 Shares of Illumina, Inc. (NASDAQ:ILMN)

July 17 at 3:45 AM | marketbeat.com

Illumina, Inc. (NASDAQ:ILMN) Holdings Trimmed by M&T Bank Corp

July 16, 2025 | marketbeat.com

Envestnet Asset Management Inc. Reduces Stock Position in Illumina, Inc. (NASDAQ:ILMN)

July 16, 2025 | marketbeat.com

HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?

July 15, 2025 | zacks.com

OVERSEA CHINESE BANKING Corp Ltd Has $47.07 Million Stock Position in Illumina, Inc. (NASDAQ:ILMN)

July 14, 2025 | marketbeat.com

Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Raised by Slow Capital Inc.

July 14, 2025 | marketbeat.com

Illumina, Inc. (NASDAQ:ILMN) Stock Position Raised by Stephens Investment Management Group LLC

July 14, 2025 | marketbeat.com

Illumina (NASDAQ:ILMN) Stock Rating Lowered by Scotiabank

July 14, 2025 | americanbankingnews.com

Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Recommendation of "Hold" from Brokerages

July 14, 2025 | americanbankingnews.com

Illumina, Inc. (NASDAQ:ILMN) Given Average Rating of "Hold" by Analysts

July 14, 2025 | marketbeat.com

Notable healthcare headlines for the week: Trump’s tariff threat, Merck, UnitedHealth and Moderna in focus

July 13, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALGN, BSX, ARGX, and ILMN Company Descriptions

Align Technology NASDAQ:ALGN

$190.77 -1.50 (-0.78%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$191.03 +0.26 (+0.14%)

As of 07/18/2025 07:57 PM Eastern

Align Technology, Inc. designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth. The segment also provides Invisalign moderate, lite and express packages, and Invisalign go and Invisalign Go Plus; retention products, Invisalign training, and adjusting tools used by dental professionals during the course of treatment; and Invisalign Palatal Expander, a 3D printed orthodontic device; and 3D printing solutions. Its Imaging Systems and CAD/CAM Services segment offers iTero intraoral scanning system, a single hardware platform for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and orthodontists software for digital records storage, orthodontic diagnosis, and fabrication of printed models and retainers. This segment also provides Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; Align Oral Health Suite, a digital interface designed to enhance dental consultations; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan, as well as subscription software, disposables, rentals, leases, pay per scan, and CAD/CAM software solutions. The company was incorporated in 1997 and is headquartered in Tempe, Arizona.

argenex NASDAQ:ARGX

$564.59 -8.12 (-1.42%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$564.54 -0.06 (-0.01%)

As of 07/18/2025 05:15 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Boston Scientific NYSE:BSX

$103.68 -0.97 (-0.93%)

Closing price 07/18/2025 03:59 PM Eastern

Extended Trading

$103.63 -0.05 (-0.05%)

As of 07/18/2025 08:00 PM Eastern

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Illumina NASDAQ:ILMN

$96.14 -1.79 (-1.83%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$96.12 -0.03 (-0.03%)

As of 07/18/2025 07:55 PM Eastern

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time